Overview
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
Status:
Recruiting
Recruiting
Trial end date:
2025-12-15
2025-12-15
Target enrollment:
0
0
Participant gender:
All
All
Summary
A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2204Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
JW Pharmaceutical
Criteria
Inclusion Criteria:- Type 2 Diabetes Mellitus
Exclusion Criteria:
- Type 1 Diabetes Mellitus
- The subject not meet the specified HbA1c and FPG